Korea Q2 Roundup: New Drugs Drive Growth, First-Line Lazertinib Approval
New Indications For U-Turned Assets, 'Glocalization'
Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.
![Quarterly report](https://insights.citeline.com/resizer/v2/F2KGOUFMCFKURBPDMBZBABRM54.jpg?smart=true&auth=d93ff7dfa7a1676c25c9ac64c07331bc4d58037da2b82b6264455082878fc350&width=700&height=394)